Atai Life Sciences (ATAI): Assessing an Expensive-Looking Valuation After a Strong Share Price Run [Yahoo! Finance]
AtaiBeckley Inc. (ATAI)
US:NASDAQ Investor Relations:
ir.atai.net.cn
Company Research
Source: Yahoo! Finance
See our latest analysis for Atai Beckley. The latest pullback has not undone what has been a powerful run, with Atai Beckley posting a year to date share price return of 161.88 percent and a 1 year total shareholder return of 240.65 percent. This suggests momentum is still very much in play even after some volatility. If the recent swings in Atai Beckley have you rethinking your healthcare exposure, this is a good moment to explore other potential ideas through healthcare stocks With a still tiny revenue base, a widening clinical pipeline, and a stock that trades at a steep discount to analyst targets, the key question now is whether this is a genuine buying opportunity or if markets are already pricing in future growth. At a last close of $4.19, Atai Beckley changes hands at a rich looking price to book ratio of 9.5 times versus more traditional drug makers. The price to book multiple compares the market value of the equity to the accounting value of its net assets. This l
Show less
Read more
Impact Snapshot
Event Time:
ATAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATAI alerts
High impacting AtaiBeckley Inc. news events
Weekly update
A roundup of the hottest topics
ATAI
News
- AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish [Seeking Alpha]Seeking Alpha
- BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 InitiationGlobeNewswire
- BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor DayGlobeNewswire
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsPR Newswire
- AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 [Yahoo! Finance]Yahoo! Finance
ATAI
Earnings
- 11/12/25 - Miss
ATAI
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 3
- 2/26/26 - Form 144
- ATAI's page on the SEC website